ReviewDrug design, development and therapy2015

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.

Stephan Herbertz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.